< Back to search
Filter
1

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

for
Hematologic Malignancy, ALL, Childhood, AML, Childhood,
Location: Memphis TN
Sponsor: St. Jude Children's Research Hospital

Sex: All

Age: 0 - 21

Code: NCT06326463

Phase1, Recruiting

UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy

for
AML, ALL, Lymphoid Malignancies, Myelodysplastic Syndromes, CML,
Location: Birmingham AL
Sponsor: University of Alabama at Birmingham

Sex: All

Age: 0 - 70+

Code: NCT06047886

Phase1, Recruiting

DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

for
Leukemia, Myeloid, Acute
Location: Burlington VT, Charlottesville VA, Winston-Salem NC,
Sponsor: Delta-Fly Pharma, Inc.

Sex: All

Age: 18+

Code: NCT06382168

Phase1, Phase2, Recruiting

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

for
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute,
Location: Boston MA, New Brunswick NJ, Morristown NJ,
Sponsor: Sumitomo Pharma America, Inc.

Sex: All

Age: 12+

Code: NCT04988555

Phase1, Phase2, Recruiting

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

for
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia,
Location: Winston-Salem NC
Sponsor: Wake Forest University Health Sciences

Sex: All

Age: 18 - 70+

Code: NCT01890486

Recruiting

Interested in new acute myeloid leukemia trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

for
Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML,
Location: New Haven CT, Durham NC, Miami FL, Columbus OH,
Sponsor: Aptose Biosciences Inc.

Sex: All

Age: 18+

Code: NCT03850574

Phase1, Phase2, Recruiting

Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder

for
RUNX1 Familial Platelet Disorder
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18 - 70+

Code: NCT06414889

Phase1, Recruiting

Assessment of Geriatric Evaluations Impact on New AML Guidance

for
AML, Adult
Location: Philadelphia PA
Sponsor: Abramson Cancer Center at Penn Medicine

Sex: All

Age: 50+

Code: NCT05909501

Recruiting

CC-486 and Venetoclax for Acute Myeloid Leukemia

for
AML
Location: Aurora CO
Sponsor: University of Colorado, Denver

Sex: All

Age: 18 - 70+

Code: NCT05287568

Phase1, Recruiting

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

for
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT04239157

Phase2, Recruiting

Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML

for
AML
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT07508982

Phase1, Phase2, Recruiting

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

for
Relapsed Adult AML, Refractory AML, Acute Myelogenous Leukemia
Location: Minneapolis MN
Sponsor: Masonic Cancer Center, University of Minnesota

Sex: All

Age: 18+

Code: NCT07591649

Phase1, Phase2, Recruiting

Cord Blood Transplantation in Children and Young Adults With Blood Cancer

for
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia,
Location: New York NY
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 0 - 26

Code: NCT07566377

Phase2, Recruiting

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

for
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes,
Location: New York NY, Hackensack NJ, Tampa FL, Nashville TN,
Sponsor: Orca Biosystems, Inc.

Sex: All

Age: 18+

Code: NCT07216443

Phase2, Recruiting

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

for
AML, MDS
Location: Boston MA, New Haven CT, New York NY, Hackensack NJ,
Sponsor: TScan Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07702578

Phase3, Recruiting

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

for
IDH1 Mutation, Relapsed / Refractory AML
Location: Winston-Salem NC
Sponsor: Timothy Pardee

Sex: All

Age: 18+

Code: NCT07471841

Phase2, Recruiting

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

for
Myelodysplastic Syndrome(MDS), Acute Myelogenous Leukemia (AML)
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06548230

Phase1, Phase2, Recruiting

A Long Term Follow-up Study of TScan TCR-T Products

for
AML, ALL, MDS
Location: New York NY, Duarte CA
Sponsor: TScan Therapeutics, Inc.

Sex: All

Age: 18 - 70+

Code: NCT06976736

Recruiting

A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease

for
AML
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 65 - 70+

Code: NCT06973668

Phase2, Recruiting

Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood

for
aGVHD, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia,
Location: Cleveland OH
Sponsor: Case Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT06904482

Phase2, Recruiting